http://orcid.org/0000-0002-0719-2469
Figures
Abstract
The BH3-only apoptosis agonists BAD and NOXA target BCL-2 and MCL-1 respectively and co-operate to induce apoptosis. On this basis, therapeutic drugs targeting BCL-2 and MCL-1 might have enhanced activity if used in combination. We identified anti-leukaemic drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism using the technique of dynamic BH3 profiling, whereby cells were primed with drugs to discover whether this would elicit mitochondrial outer membrane permeabilisation in response to BCL-2-targeting BAD-BH3 peptide or MCL-1-targeting MS1-BH3 peptide. We found that a broad range of anti-leukaemic agents–notably MCL-1 inhibitors, DNA damaging agents and FLT3 inhibitors–sensitise leukaemia cells to BAD-BH3. We further analysed the BCL-2 inhibitors ABT-199 and JQ1, the MCL-1 inhibitors pladienolide B and torin1, the FLT3 inhibitor AC220 and the DNA double-strand break inducer etoposide to correlate priming responses with co-operative induction of apoptosis. ABT-199 in combination with pladienolide B, torin1, etoposide or AC220 strongly induced apoptosis within 4 hours, but the MCL-1 inhibitors did not co-operate with etoposide or AC220. In keeping with the long half-life of BCL-2, the BET domain inhibitor JQ1 was found to downregulate BCL-2 and to prime cells to respond to MS1-BH3 at 48, but not at 4 hours: prolonged priming with JQ1 was then shown to induce rapid cytochrome C release when pladienolide B, torin1, etoposide or AC220 were added. In conclusion, dynamic BH3 profiling is a useful mechanism-based tool for understanding and predicting co-operative lethality between drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism. A plethora of agents sensitised cells to BAD-BH3-mediated mitochondrial outer membrane permeabilisation in the dynamic BH3 profiling assay and this was associated with effective co-operation with the BCL-2 inhibitory compounds ABT-199 or JQ1.
Citation: Grundy M, Seedhouse C, Jones T, Elmi L, Hall M, Graham A, et al. (2018) Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling. PLoS ONE 13(1): e0190682. https://doi.org/10.1371/journal.pone.0190682
Editor: Andrei L. Gartel, University of Illinois at Chicago, UNITED STATES
Received: August 15, 2017; Accepted: December 19, 2017; Published: January 3, 2018
Copyright: © 2018 Grundy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by the Nottinghamshire Leukaemia Appeal, Chairperson Mrs Sylvia Bishton (nla-appeal.org) Project grant to MG and the Nottingham University Hospitals Charity (nottinghamhospitalscharity.org.uk) Pump priming grant to NR and MP. The funders had no role in the study design, data collection, decision to publish or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Background
The modes of action of diverse cytotoxic agents generally converge on mitochondrial apoptotic pathways [1]. To allow apoptosis to occur, effector molecules BAX and BAK must oligomerise to form pores that cause mitochondrial outer membrane permeabilisation (MOMP). BAX and BAK activation can be triggered by BH3-only proapoptotic BCL-2 family members such as BID and BIM, PUMA, BAD and NOXA. These are opposed by BCL-2 family prosurvival members, such as MCL-1 and BCL-2 itself, that sequester pro-apoptotic family members to hold apoptosis in check. Effective pro-apoptotic drugs alter the equilibrium of the system, both by altering relative levels of the pro-and anti-apoptotic BCL-2 family members and triggering changes of phosphorylation, conformation and location [1, 2].
Monotherapies are not successful at inducing remissions in patients with acute myeloid leukaemia. With many new drugs on the market or in the pipeline [3, 4], there is a need to establish rational principles for predicting suitable drug combinations. One such principle is co-operation between agents that activate complementary components of pro-apoptotic pathways. For example, the sensitiser molecule BAD is ineffective against MCL-1, and NOXA is ineffective against BCL-2, but there is direct co-operation between BAD and NOXA in mediating apoptosis [5], suggesting that therapeutic agents that inhibit BCL-2 may complement agents that inhibit MCL-1. Indeed, several studies have now shown synergy between specific BCL-2 and MCL-1 antagonists [6–10]. Mechanistically, when BCL-2 is inhibited, e.g. by the binding agents ABT-737 or ABT-199, the apoptosis activator BIM is released [7, 10–13], but the released BIM can then be taken up by MCL-1, so protection from apoptosis is maintained unless MCL-1 is also antagonised [10, 14–16].
There is currently great interest in discovering the ability of different classes of therapeutic agents to synergise with BCL-2 or MCL-1 antagonists [8, 10, 14–23]. As MCL-1 has a short half-life (approximately 1 hour) [24] it can be rapidly downregulated, as reported after treatment with ultraviolet radiation [25] or sorafenib [26] for 3 hours or less. It is unclear whether this is crucial for induction of apoptosis, since other factors, such as induction of BIM, NOXA or PUMA are also reported. BCL-2 is a much more stable protein than MCL-1, with a protein half-life of approximately 14 hours [27, 28]. BCL-2 downregulation can be effected by BET domain inhibitors, but whereas message downregulation occurs rapidly in sensitive cells, protein loss takes place over a much longer time period [29]. In contrast, BCL-2 binding antagonists such as ABT-737 or ABT-199 (venetoclax) [30, 31] can act rapidly to induce apoptosis in sensitive cells.
Whilst several authors have documented the efficacy of the BCL-2 antagonists ABT-199 and ABT-737 at co-operating with agents that downregulate or bind MCL-1 [6, 8, 10, 16–19, 21, 22], the literature is focused on individual drug combinations. In the current study we use a variety of drugs and chemical inhibitors to systematically identify agents sensitising to BCL-2 antagonism and agents sensitising to MCL-1 antagonism. Dynamic BH3 profiling [32] is a novel methodology that measures the capacity of drugs to prime mitochondria for apoptosis, and involves the addition of permeable pro-apoptotic BCL-2 family BH3 peptides to drug primed cells to induce speedy mitochondrial outer membrane permeabilisation (MOMP). In this study we measure MOMP after applying BAD (BCL-2 targeting) or MS1 (MCL-1 targeting) BH3 peptides to the drug-primed cells. Induction of MOMP is measured here with a cytochrome C release assay [33]. Applying this technique previously, we had shown that the MCL1 downregulator TG02 sensitises to the BCL-2-inhibitory BAD-BH3 peptide, whereas the BCL-2 antagonist ABT-199 sensitises to MCL-1 inhibitory NOXA-BH3 peptide, and the two agents synergise in dual-sensitive cells to induce apoptosis [18]. We dichotomise drugs as either agents sensitising to BCL-2 antagonism or agents sensitising to MCL-1 antagonism, and we demonstrate the efficacy of combining an agent from each category in apoptosis assays.
Materials and methods
Materials
Drugs and suppliers used in the study were as follows: 17-AAG, rapamycin, sorafenib and torin1 from LC labs (www.lclabs.com); AC220, JQ1, selinexor, tosedostat, TW-37 and vosaroxin from Selleck (supplied by Stratech UK); ABT-199 from Adooq, www.adooq.com; ABT-737 from Sequoia, Pangbourne, UK; A-1210477 from Chemie Tek, www.chemietek.com; etoposide from Tocris, Bristol, UK; Mylotarg from Wyeth, Pearl River USA; Pladienolide B from Santa Cruz, supplied by Insight, Wembley, UK; TG02 was from Tragara, San Diego, USA. Other drugs and reagents were from Sigma (Poole, Dorset, UK) unless specified.
Cells
The MV4.11 cell line was from the American Tissue Culture Collection (Manassas, USA) and was maintained in RPMI 1640 medium with 10% foetal calf serum (FCS; First Link, Birmingham, UK), and 2mM L-glutamine. All cultures were kept at 37°C in 5% CO2 and all experiments were performed with cell lines in log phase. Continued testing to authenticate these cell lines was performed using multiplex short tandem repeat analysis (Powerplex 16, Promega, Southampton, UK). Mycoplasma testing was carried out routinely using the Mycoalert mycoplasma detection kit (Lonza, Rockland, USA) and following the manufacturer’s instructions.
Dynamic BH3 profiling
MV4.11 cells were incubated (5 X 105/ml) in RPMI with 10% FCS for four hours with the indicated drugs. Cytochrome C release (using Alexa-647-conjugated cytochrome C antibody, BD #558709) was measured by flow cytometry after a further 60 minute incubation of digitonin-permeabilised cells with BH3 peptides as described [18, 33]. Adjustments for peptide induced cytochrome C release in untreated cells were made in order to establish agent-specific release (delta priming), using the formula (percent release with agent and peptide–percent release with peptide)/ (100 –percent release with peptide). A mutated PUMA-BH3 peptide (PUMA2A) [33] was used at 100 μM as control in all experiments.
Determination of apoptosis
Cytochrome C release, loss of mitochondrial membrane potential (↓Δψm) and uptake of 7-amino-actinomycin D were measured by flow cytometry.
To measure the percentage of cells with loss of Cytochrome C, cells were fixed in 2% paraformaldehyde directly after a 4 hour drug incubation. Fixed and rinsed cells were permeabilised with saponin and incubated overnight with Alexa-647-conjugated cytochrome C antibody and analysed by flow cytometry.
The percentage of cells with loss of mitochondrial membrane potential (↓Δψm) was determined following incubation of cells as previously reported [34] with the fluorescent dye 3,3’–dihexyloxacarbocyanine iodide (DiOC6, 40 nM, Molecular Probes, Oregon) for the final 75 minutes of a 5 ¼ hour drug incubation, with 0.5 μg/ml 7-aminoactinomycin D (7-AAD) also added for the final 30 minutes to measure a later stage of apoptosis [35].
Protein measurement
Protein expression of 4E-BP1 p-thr36/45, BD#560286) and BCL-2 (Ancell #357–040) were measured by flow cytometry. MCL-1L (long) and MCL-1S (short) forms were measured by Western Blotting using the sc-819 antibody from Santa Cruz.
MCL1 mRNA short and long form measurement
Expression levels of Mcl-1L and Mcl-1S using cDNA from AML cell lines were determined quantitatively by qRT-PCR on an ABI Prism 7500 (Applied Biosystems) using SYBR Green Master Mix (Applied Biosystems). Specific amplification of the isoforms was achieved using primers with previously reported sequences [36]. Gene expression levels were normalized to beta-2-microglobulin (β2m) housekeeping gene expression [37]. Negative controls (no template) were included in all the experiments and the reactions were run in triplicate.
Calculations and statistics
Fold excess addititivism was calculated as a ratio of observed to expected values for drug combinations, where the expected value C is calculated from the Bliss algorithm for response to two compounds with effects A and B i.e. C = A + B–A*B [38, 39]. This method allows for potentiation and augmentation as well as synergism. Statistics were carried out using SPSS version 22 software (Chicago, IL, USA). P values <0.05 were considered statistically significant.
Results
1. Methodology
MV4-11 cells were used for screening drugs, as these cells were highly sensitive to apoptosis induced by either BCL-2 or MCL-1 targeting (S1 Fig). These cells do not over-express BCL-XL [18]. Montero and colleagues [32] have described the technique of dynamic BH3 profiling, which involves using short drug exposures to prime mitochondria for BH3 peptide-induced Cytochrome C release, and these authors demonstrated that the assay could predict cytotoxicity. Dynamic BH3 profiling relies on the ability of a drug and a BH3-only pro-apoptotic peptide to induce MOMP in cells when used in combination: sensitivity is compromised if the agent or peptide induce too much apoptosis individually, so it is crucial to establish suitable drug concentrations for the assay. To allow drugs to prime cells as single agents, but not to kill them outright during the course of the assay, we established a suitable incubation time and drug concentrations by screening with a PUMA-BH3 peptide which can sensitise all the anti-apoptotic BCL-2 family proteins [28]. We defined appropriate priming concentrations of agents as those that induced >75% Cytochrome C release in the presence of PUMA-BH3 but less than 10% when incubated with a control peptide, i.e. a >65% change in priming (“Δ priming”, Fig 1). The data show that a variety of agents prime to PUMA-BH3 after as little as four hours. Agents used in the study along with their proposed mechanism of sensitising to apoptosis are delineated in Table 1. We grouped agents into four main categories. The first category comprised agents expected to strongly inhibit MCL-1. The second category of agents comprised BCL-2 antagonists. Agents which induce double strand breaks (etoposide, mylotarg, and vosaroxin—category 3) and FLT3 inhibitors (AC220, sorafenib—category 4) were also studied. All the agents studied primed to PUMA-BH3 after a four-hour incubation with the exception of JQ1. Rationales and results for priming to PUMA-BH3 for several additional agents (miscellaneous, category 5) are shown in S2 Fig.
The increase in cells primed to undergo mitochondrial outer membrane depolarisation (Δ priming) is measured by Cytochrome C release after 4 hour drug treatment. PUMA-BH3 was used at 3 μM. Values are corrected for Cytochrome C release with peptide only as described in the methods. (Mean+/- SD for n = 3).
We previously showed that the MCL-1 reducing agent TG02 primes AML cells to respond to BCL2 antagonism and that ABT-199 primes cells to respond to MCL-1 antagonism [18]. In that assay a NOXA-BH3 peptide was used to antagonise MCL-1. However we refined the methodology for the current study following reports that the MS1 peptide binds to MCL-1 with higher affinity than NOXA-BH3 [52]. In MV4.11 cells the concentration of MS-1 required to complement ABT-199 was 10-100-fold less than that of NOXA-BH3 (S3 Fig). On the basis of this data we selected 3 μM BAD-BH3 and 3 μM MS1-BH3 for the complementary profiling assay.
2. Co-operative dynamic BH3 profiling
Cells were incubated for four hours with agents of interest followed by dynamic BH3 profiling. Diverse agents sensitised cells to BAD-BH3, indicating that the four hour drug incubation had increased the BCL-2 dependence of the cells and thus enabled the cells to cross the threshold for apoptosis once the BCL-2 antagonist peptide was added (Fig 2A and S4 Fig). In contrast, only the highly specific BCL-2 antagonist ABT-199 and the BCL-2/BCL-XL antagonist ABT-737 primed to equimolar (3 μM) MS1: i.e. after priming with a variety of drugs, MCL-1 antagonism with MS1-BH3 did not generally enable the cells to cross the threshold for apoptosis (Fig 2B and S4 Fig).
Dynamic BH3 profiling assay: delta priming to (A) BAD-BH3 and (B) MS1-BH3 peptides. Delta priming is measured by cytochrome C release after 4 hour drug treatment and additional incubation with the indicated BH3 peptides (BAD-BH3 at 3 μM, MS1-BH3 at 3 μM, PUMA2A control at 100 μM). Values are corrected for cytochrome C release with peptide only as described in the methods. (Mean+/- SD for n = 3).
3. Co-operative induction of apoptosis
On the basis of the BAD-BH3 and MS1-BH3 profiling, we investigated whether the cells would be sensitive to a combination of BCL-2 and MCL-1 antagonists. ABT-199 is well described as a powerful BCL-2 antagonist at nanomolar concentrations in AML cells [53]. From the data illustrated in Fig 2A, we selected two MCL-1 antagonists: pladienolide B and torin1. The spliceosome inhibitor pladienolide B is reported to rapidly induce alternative splicing of MCL-1 from the anti-apoptotic long form to the pro-apoptotic short form [40]. At 10 nM, pladienolide had primed for >99% sensitisation to BAD-BH3 (Fig 2A). We confirmed the reported alternative splicing mechanism in our system and the rapid loss of MCL1 protein (Fig 3A). We also used the powerful chemical mTORC1 antagonist torin1 [42] to inhibit translation, because translational activation by oncogenic kinases is a widespread phenomenon in AML, via STAT5, PIM, ERK and PI3K pathways, which all act on translation initiation factors. Inhibition of translation depletes MCL-1 protein [54]. We confirmed that torin1 dephosphorylates the translational activator 4E-BP1 and depletes MCL-1 in the MV4.11 cells (Fig 3B). A supra-additive effect of combining ABT-199 with either pladienolide B or torin1 to induce cytochrome C release was documented, but no complementary MOMP or apoptosis was detected when MCL-1 targeting agents were used with each other (Fig 3C and 3D).
(A) MCL-1 long form (L) and short form (S) transcripts (i) and protein (ii) were quantified in untreated cells and cells treated with 10 nM pladienolide B (PLB) for 4 hours. (B) 4E-BP1 phosphorylation (i) and MCL-1 protein (ii) were quantified in untreated cells and cells treated with 1μM torin1 for 4 hours. (C, D) Cells were incubated with 10 nM ABT-199 (199, turquoise), 10 nM pladienolide B (PLB, red), 1 μM torin1 (green) or the indicated combinations (bright blue bar, height = effect with both agents in combination–sum of effects with agents individually). (C) After 4 hours cells were fixed and processed for Cytochrome C release. (D) After 4 hours DiOC6 was added for a further 75 minutes and 7-amino actinomycin D for the last 30 minutes. (Mean+/- SD for n = 3). Fold excess additivism (FEA) is shown on the figures and was calculated as a ratio of observed to expected values after corrections according to the Bliss algorithm (see methods). Asterisks indicate observed values significantly higher than expected values (P<0.05).
We expanded the study to include a DNA damage-inducing agent and a FLT3 inhibitor, since these categories of agent are of particular clinical interest in AML and had sensitised to BAD-BH3 in the dynamic BH3 profiling assay. Combining the double strand break-inducing agent etoposide or the FLT3 inhibitor AC220 with ABT-199 led to early MOMP and apoptosis (Fig 4), whereas combining the agents with pladienolide B or torin1 did not have significant pro-apoptotic effects. Flow cytometric illustrations of apoptosis in treated cells are shown in S5 Fig.
Cells were incubated with 10 nM ABT-199 (199, turquoise), 10 nM pladienolide B (PLB, red), 1 μM torin1 (green), 1 μM etoposide (orange) and 10 nM AC220 (mauve) or the indicated combinations (bright blue bar, height = effect with both agents in combination–sum of effects with agents individually). (A) After 4 hours cells were fixed and processed for Cytochrome C release. (B) After 4 hours DiOC6 was added for a further 75 minutes and 7-amino actinomycin D for the last 30 minutes. (Mean+/- SD for n = 3). Fold excess additivism (FEA) is shown on the figures and was calculated as a ratio of observed to expected values after corrections according to the Bliss algorithm (see methods). Asterisks indicate observed values significantly higher than expected values (P<0.05).
4. Delayed co-operative induction of apoptosis: JQ1 as a BCL-2 antagonist
The pattern observed thus far of common MCL-1 antagonism and rare BCL-2 antagonism is likely, at least in part, to be predicated on differences in the stability of the two proteins. MCL-1 has a very short half-life (approximately one hour) [24] which makes it extremely susceptible to rapid downregulation when protein synthesis is decreased or degradation pathways are activated [28, 54]. BCL-2 however, has a much longer half-life (10–14 hours)[27], such that where an agent downregulates BCL-2 at the message level, it may take several hours for functional consequences to be observed. The BET domain inhibitor JQ1 is documented to downregulate BCL-2 [29] and therefore might acquire the capacity to prime for an MS1 (MCL1-antagonist) response. In MV4-11 cells BCL-2 protein downregulation was noted which plateaued at approximately 48 hours, and JQ1 was able to prime to MS-1 BH3 after 48 hours of incubation (Fig 5A and 5B). Cells were therefore incubated with JQ1 for 48 hours with addition of additional agents for the final four hours. JQ1 was found to prime cells to pladienolide, torin1, etoposide and AC220 (Fig 5C). No significant interaction was observed between JQ1 and ABT-199.
(A) Time course of bcl-2 protein downregulation in response to JQ1 measured by flow cytometry. MFI = mean fluorescence intensity, corrected for isotype control. (B) Time course of delta priming to BAD-BH3 and MS1-BH3 measured by cytochrome C release after drug treatment and additional incubation with the indicated BH3 peptides. Values are corrected for Cytochrome C release with peptide only as described in the methods. (C) Cells were incubated with 250 nM JQ1 for 2 days. 10nM pladienolide B (PLB), 1 μM torin1, 10nM ABT-199 (199), 1 μM etoposide (ETO) or 10 nM AC220 were added for the final 4 hours. Cells were then fixed and processed for Cytochrome C release. Bright blue bar height = cytochrome C release with both agents in combination–sum of cytochrome C release with both agents individually). Fold excess additivism is shown on the figures and was calculated as a ratio of observed to expected values after corrections according to the Bliss algorithm (see methods). Asterisks indicate observed values significantly higher than expected values (P<0.05). (Mean+/- SD for n = 3).
5. Scheduling-specific dependence of co-operation between ABT-199 and the MCL-1 antagonist A-1210477
The specific MCL1 binding inhibitor A-1210477 is an in vitro chemical tool that had not been used in our earlier panel as it induced apoptosis in its own right at high concentrations (> 3μM) but failed to prime to BAD-BH3 at sub-micromolar concentrations (S6 Fig). We nevertheless decided to investigate it further because of its specificity for MCL-1 [6]. A supra-additive effect of combining ABT-199 or JQ1 with 1 μM A-1210477 to induce cytochrome C release was documented, but no enhancement of cytochrome C release was detected when A-1210477 was used with the MCL-1 downregulating agents pladienolide B or torin1 or with etoposide or AC220 (Fig 6A), thus providing further evidence of the particular efficacy of combining BCL-2 antagonists with MCL-1 antagonists. As the BH3 profiling assay had not predicted the co-operative potential of 1 μM A-1210477 with BCL-2 antagonists, we investigated this anomaly. A possible explanation is predicated on the fact that, in the BH3 profiling assay, the MCL-1 antagonist A-1210477 and the BCL-2 antagonist (BAD-BH3 peptide) are added to cells sequentially, possibly allowing pro-apoptotic activators such as BIM and PUMA to return to an undepleted pool of MCL-1 when the cells are washed in preparation for addition of peptide in permeabilisation buffer, whereas in the apoptosis experiments A-120477 and ABT-199 are incubated with cells simultaneously. An assay in which we compared sequential with concurrent use of ABT-199 and A-1210477 showed that A-1210477 was indeed ineffective when incubated with cells for four hours and washed off before a two hour incubation with ABT-199 (Fig 6B). However the reverse sequence, i.e. applying ABT-199 before A-1210477, was as effective as using the two agents concurrently.
A. Cells were co-incubated with 1 μM A-1210477 (477) and with 10 nM ABT-199 (199), 10nM pladienolide B (PLB), 1 μM torin1, 1 μM etoposide or 10 nM AC220 for 4 hours. Alternatively, cells were incubated with JQ1 for 48 hours and A-1210477 was added for the final four hours of the incubation. Cells were then fixed and processed for Cytochrome C release. (Mean+/- SD for n = 3). B. Cells were incubated with 1 μM A-1210477 for four hours and 10 nM ABT-199 was added either before, after or concurrently (final 2 hours). In the two-step conditions, cells were pelleted and rinsed twice in RPMI at 4°C in between agents. R10 = medium without drug.
Discussion
The technique of co-operative dynamic BH3 profiling has shown that a range of anti-AML drugs and chemical inhibitors sensitise to BCL-2 antagonism and a much smaller number of agents (ABT-199, ABT-737 and JQ1) sensitise to MCL-1 antagonism. MCL-1 and BCL-2 are both guardians of mitochondrial integrity, protecting the healthy cell by sequestering pro-apoptotic BCL-2 family members but allowing controlled release of the pro-apoptotic molecules in response to appropriate stresses. The technique provided evidence that many drugs cause early (within 4 hours) pro-apoptotic changes in cells. Dynamic BH3 profiling does not specify exactly which molecules are effecting these pro-apoptotic changes, but it does show whether these changes can be complemented by specifically antagonising BCL-2 or MCL-1. We add the caveat that A-1210477, and likely other transient binding agents, do not work well in this assay.
Although often described together, there are important functional differences between MCL-1 and BCL-2 which bear upon the findings of the current study. MCL-1 is an unstable protein with a very short half-life [24, 28, 54]. Its rapid destruction may be a common factor in cellular responses to stresses, such that the propensity of major drug types to downregulate MCL-1 may be a dominant cause of sensitising cells to BCL-2 antagonism. Brunelle and colleagues documented that BCL-2 overexpression conferred resistance to a range of chemotherapeutic agents, but the same agents were effective in MCL-1 over-expressing cells. Moreover MCL-1 protein was depleted in sensitive, drug-treated cells [47]. Priming to BCL-2 inhibitors is not exclusively through MCL-1 downregulation: alternative pathways have been documented [55, 56], but a lot of evidence points to MCL-1 downregulation being a very common feature of chemo responsiveness (see Introduction, Table 1 and Fig 3). An inference here might be that MCL-1 binding antagonists become redundant where the drug has caused protein depletion. This could account for the lack of interaction between the antagonist A-1210477 and the spliceosome inhibitor pladienolide or the mTOR inhibitor torin1 in our study, both of which ablated MCL-1. From a different angle, MCL-1 binding antagonists may be useful to supplement the MCL-1 depleting effects of less efficient agents, particularly in vivo. Also, the apparent lack of avidity of A-1210477 binding (Fig 6), draws attention to the complication that, whereas transient MCL-1-binding agents may have an advantage in reducing toxicity in a clinical setting, their efficacy in combination with BCL-2 inhibitors may require co-administration.
In contrast to the MCL-1 depleting abilities of many drugs, agents that inhibit BCL-2 are uncommon. ABT-199 has been well characterised in the literature and is being used (as venetoclax) in the clinic. BET domain inhibitors and their interactions with other drugs are less well characterised, but there is currently huge interest in their development [57]. Although BCL-2 downregulation by JQ1 and associated sensitisation to MS1-BH3 were documented in our study, we add the caveat that BET domain inhibitors are highly non-specific and have numerous additional targets [29].
The current set of experiments is applicable to agents that elicit rapid pro-apoptotic changes, which could be a useful strategy to pre-empt protective stress responses. Agents as diverse as etoposide and AC220 sensitised powerfully to BAD-BH3 after just 4 hours (Fig 2). We did not find complementary dynamic BH3 profiling to be useful in the context of nucleoside analogues ara-C or 5-azacytidine, which elicited only weak priming to BAD-BH3 (S4 Fig) or with ABT-199 in 4 hour apoptosis experiments (data not shown). We also did not find the dynamic profiling assay to be useful for predicting synergy in 48 hour dose response assays (data not shown), so the current findings are likely confined to early interactions. The original dynamic BH3 profiling work found correlations between 16-hour drug priming to BIM-BH3 and 72 hour apoptosis [32], so our much shorter, four-hour, culture is likely to be particularly relevant to agents with early pro-apoptotic effects.
In a clinical setting, the combination of an agent sensitising to BCL-2 antagonism and one sensitising to MCL-1 antagonism could be useful in a synthetic lethal combination, such as the combination of ABT-199 or a BET domain inhibitor with the FLT3 inhibitor AC220 documented in Figs 4 and 5. FLT3 internal tandem duplications affect 30% of AML patients [58]. The decision to use FLT3 inhibitors in this study was based on work showing the downregulation of MCL-1 to be a consequence of inhibition of translation initiation by sorafenib [26]. FLT3 internal tandem duplications drive constitutive activation of STAT5 and PI3K, both of which can drive MCL-1 overexpression through the translation initiation complex [59], such that MCL-1 downregulation is likely to be a common effect of diverse FLT3 inhibitors. Synergy between JQ1 and AC-220 has been reported [60]. The spliceosome inhibitor pladienolide B was also highly effective in combination with ABT-199 or JQ1 in the current study. Early evidence suggests that targeting of the spliceosome in cases of MDS or AML with spliceosome mutations could be effective [61].
The MV4-11 cells used in this study were sensitive to either BCL-2 or MCL-1 inhibition, and were used in order to focus on differences between drugs, rather than differences between cells. Cellular dependence on different members of the BCL-2 family is highly heterogeneous, even within a single disease such as AML, and possibly even within different clones from a single patient. Considerable further work will be needed to document the efficacy of co-operative drug combinations in cells with different BCl-2 family dependencies. In a previous report we showed that the complementarity between ABT-199 and TG02 was synergistic in some cases of AML, whereas in other cases we showed the combination to be effective when one or other of the agents alone was ineffective [18].
In conclusion we have used dynamic BH3 profiling to demonstrate that drugs sensitising to BCL-2 antagonism and drugs sensitising to MCL-1 antagonism can be systematically identified and to determine that dynamic co-operative BH3 profiling can predict drug combinations that induce rapid apoptosis.
Supporting information
S1 Fig. Sensitivity to ABT-199 and TW-37 in AML cell lines.
We antagonised BCL-2 with ABT-199 [31] and MCL-1 with TW-37 [44]. The IC50s shown were obtained from alamar blue assays after treating 11 AML cell lines at a starting cell concentration of 2.5x105 /ml for 48 hours. Each cell line thawed is tested around the time of its final passage to authenticate its provenance using the Powerplex 16 kit (Promega, Southampton, UK) to amplify short tandem repeats. The reactions are run on a 3130 Genetic Analyser and data analysed using Genemapper. Mycoplasma testing was carried out routinely using the Mycoalert mycoplasma detection kit (Lonza, Rockland, USA) and following the manufacturer’s instructions.
https://doi.org/10.1371/journal.pone.0190682.s001
(TIF)
S2 Fig. Dynamic BH3 profiling assay: Delta priming to PUMA-BH3 with additional anti-AML drugs.
Delta priming is measured by cytochrome C release after 4 hour drug treatment and additional incubation with 3 μM PUMA-BH3. Values are corrected for Cytochrome C release with peptide only as described in the methods). (Mean+/- SD for n = 3). Suitable priming concentrations (>65% specificity) were established for the hsp90 inhibitor 17-AAG and the CRM1 inhibitor selinexor, but other agents were less effective. Hsp90 inhibitors [62] and selinexor [63] are reported to downregulate MCL-1. Tosedostat is reported to induce NOXA [64]. The contrast in priming abilities between rapamycin and torin1 (Fig 1) merits comment: this may be explicable in terms of the rapamycin insensitive effects of mTORC1 on 4E-BP1 [42]. 5-azacytidine (5-aza) and cytosine arabinoside (ara-C) were included for general interest.
https://doi.org/10.1371/journal.pone.0190682.s002
(TIF)
S3 Fig. Dynamic BH3 profiling assay: Delta priming with TG02 and ABT-199 to BAD-BH3 and MS1-BH3 peptides.
Delta priming is measured by cytochrome C release after TG02 (50 nM) and ABT-199 (50 nM) treatment and additional incubation with the indicated BH3 peptides. Values are corrected for Cytochrome C release with peptide only as described in the methods). (Mean+/- SD for n = 3).
https://doi.org/10.1371/journal.pone.0190682.s003
(TIF)
S4 Fig. Dynamic BH3 profiling assay: Delta priming with additional anti-AML drugs to BAD-BH3 and MS1-BH3 peptides.
Delta priming is measured by cytochrome C release after drug treatment and additional incubation with the indicated BH3 peptides (BAD-BH3 at 3 μM, MS1-BH3 at 3 μM, PUMA2A control at 100 μM). Values are corrected for Cytochrome C release with peptide only as described in the methods). (Mean+/- SD for n = 3).
https://doi.org/10.1371/journal.pone.0190682.s004
(TIF)
S5 Fig. Additional indicators of co-operative induction of apoptosis by ABT-199 with pladienolide B, torin1, etoposide and AC220: FACS plots.
Cells were incubated with the indicated combinations of 10 nM ABT-199, 10 nM pladienolide B, 1 μM torin1, 1 μM etoposide or 10 nM AC220. After 4 hours cells were incubated for a further 75 minutes with DiOC6 to measure ↓Δψm. 7-AAD was added to the cells for the final 30 minutes of the incubation. The FACS plots illustrate that the treated cells stained by 7-AAD (indicating cell membrane permeability at a final stage of apoptosis) tend to lag very slightly behind cells with ↓Δψm, indicating rapid transition from ↓Δψm to irreversible apoptosis.
https://doi.org/10.1371/journal.pone.0190682.s005
(TIF)
S6 Fig. Dynamic BH3 profiling assay: A-1210477.
Delta priming is measured by cytochrome C release after A-1210477 treatment and additional incubation with the indicated BH3 peptides. Values are corrected for cytochrome C release with peptide only as described in the methods. Results from priming with 10nm pladienolide are illustrated as positive control (<10% priming without peptide, strong priming with peptide) (Mean+/- SD for n = 3).
https://doi.org/10.1371/journal.pone.0190682.s006
(TIF)
Acknowledgments
The assay for expression of MCL-1 splice variants was optimised by Maria Demosthenous and additional work was carried out by Hiyaa Alhuthali.
References
- 1. Galluzzi L, Vitale I, Vacchelli E, Kroemer G. Cell death signaling and anticancer therapy. Frontiers in oncology. 2011;1:5. Epub 2011/01/01. pmid:22655227; PubMed Central PMCID: PMC3356092.
- 2. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nature reviews Molecular cell biology. 2014;15(1):49–63. Epub 2013/12/21. pmid:24355989.
- 3. Stahl M, Lu BY, Kim TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Targeted oncology. 2017. Epub 2017/07/01. pmid:28664386.
- 4. Tamamyan G, Kadia T, Ravandi F, Borthakur G, Cortes J, Jabbour E, et al. Frontline treatment of acute myeloid leukemia in adults. Critical reviews in oncology/hematology. 2017;110:20–34. Epub 2017/01/23. pmid:28109402; PubMed Central PMCID: PMCPMC5410376.
- 5. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular cell. 2005;17(3):393–403. Epub 2005/02/08. pmid:15694340.
- 6. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell death & disease. 2015;6:e1590. pmid:25590800.
- 7. Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell death & disease. 2012;3:e366. Epub 2012/08/10. pmid:22875003.
- 8. Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood cancer journal. 2015;5:e368. Epub 2015/11/14. pmid:26565405; PubMed Central PMCID: PMCPMC4670945.
- 9. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389–99. Epub 2006/11/14. S1535-6108(06)00291-1 [pii] pmid:17097561.
- 10. Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy. 2017;2:e17012. pmid:29263915
- 11. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–88. Epub 2006/11/14. S1535-6108(06)00313-8 [pii] pmid:17097560.
- 12. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. The Journal of clinical investigation. 2007;117(1):112–21. Epub 2007/01/04. pmid:17200714; PubMed Central PMCID: PMC1716201.
- 13. Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115(16):3304–13. Epub 2010/03/04. pmid:20197552; PubMed Central PMCID: PMC2858493.
- 14. Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2012;26(4):778–87. Epub 2011/11/09. pmid:22064351; PubMed Central PMCID: PMC3604791.
- 15. Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2016;22(17):4440–51. Epub 2016/04/23. pmid:27103402; PubMed Central PMCID: PMCPMC5010519.
- 16. Chen S, Dai Y, Pei XY, Myers J, Wang L, Kramer LB, et al. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res. 2012;72(16):4225–37. Epub 2012/06/14. pmid:22693249; PubMed Central PMCID: PMC3421040.
- 17. Zhang W, Konopleva M, Ruvolo VR, McQueen T, Evans RL, Bornmann WG, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2008;22(4):808–18. Epub 2008/01/18. pmid:18200035.
- 18. Pallis M, Burrows F, Ryan J, Grundy M, Seedhouse C, Abdul-Aziz A, et al. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget. 2017;8(10):16220–32. Epub 2016/04/20. pmid:27092880; PubMed Central PMCID: PMCPMC5369958.
- 19. Iacovelli S, Ricciardi MR, Allegretti M, Mirabilii S, Licchetta R, Bergamo P, et al. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia. Oncotarget. 2015;6(31):32089–103. pmid:26392332; PubMed Central PMCID: PMC4741661.
- 20. Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–82. Epub 2016/10/28. pmid:27760111.
- 21. Larrayoz M, Blakemore SJ, Dobson RC, Blunt MD, Rose-Zerilli MJ, Walewska R, et al. The SF3B1 inhibitor spliceostatin A (SSA) elicits apoptosis in chronic lymphocytic leukaemia cells through downregulation of Mcl-1. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2016;30(2):351–60. Epub 2015/10/22. pmid:26488112.
- 22. Cencic R, Robert F, Galicia-Vazquez G, Malina A, Ravindar K, Somaiah R, et al. Modifying chemotherapy response by targeted inhibition of eukaryotic initiation factor 4A. Blood cancer journal. 2013;3:e128. pmid:23872707; PubMed Central PMCID: PMC3730203.
- 23. Bose P, Grant S. Rational Combinations of Targeted Agents in AML. Journal of clinical medicine. 2015;4(4):634–64. pmid:26113989; PubMed Central PMCID: PMC4470160.
- 24. Yang T, Kozopas KM, Craig RW. The intracellular distribution and pattern of expression of Mcl-1 overlap with, but are not identical to, those of Bcl-2. The Journal of cell biology. 1995;128(6):1173–84. Epub 1995/03/01. pmid:7896880.
- 25. Nijhawan D, Fang M, Traer E, Zhong Q, Gao W, Du F, et al. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes & development. 2003;17(12):1475–86. pmid:12783855; PubMed Central PMCID: PMC196078.
- 26. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43–9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. The Journal of biological chemistry. 2005;280(42):35217–27. Epub 2005/08/20. M506551200 [pii] pmid:16109713.
- 27. Kitada S, Miyashita T, Tanaka S, Reed JC. Investigations of antisense oligonucleotides targeted against bcl-2 RNAs. Antisense Research Development. 1993;3:157–69. pmid:8400801
- 28. Rooswinkel RW, van de Kooij B, de Vries E, Paauwe M, Braster R, Verheij M, et al. Antiapoptotic potency of Bcl-2 proteins primarily relies on their stability, not binding selectivity. Blood. 2014;123(18):2806–15. Epub 2014/03/14. pmid:24622325.
- 29. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Molecular cancer therapeutics. 2014;13(5):1142–54. pmid:24435446.
- 30. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–81. Epub 2005/05/20. nature03579 [pii] pmid:15902208.
- 31. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8. Epub 2013/01/08. pmid:23291630.
- 32. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015;160(5):977–89. pmid:25723171; PubMed Central PMCID: PMC4391197.
- 33. Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013;61(2):156–64. Epub 2013/04/24. pmid:23607990; PubMed Central PMCID: PMC3686919.
- 34. Pallis M, Grundy M, Turzanski J, Kofler R, Russell N. Mitochondrial membrane sensitivity to depolarization in acute myeloblastic leukemia is associated with spontaneous in vitro apoptosis, wild-type TP53, and vicinal thiol/disulfide status. Blood. 2001;98(2):405–13. pmid:11435310.
- 35. Philpott N, Turner A, Scopes J, Westby M, Marsh J, Gordon-Smith E, et al. The use of 7-amino Actinomycin D in identifying apoptosis: simplicity of use and broad spectrum of application compared with other techniques. Blood. 1996;87:2244–51. pmid:8630384
- 36. Goff DJ, Court Recart A, Sadarangani A, Chun HJ, Barrett CL, Krajewska M, et al. A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition. Cell Stem Cell. 2013;12(3):316–28. pmid:23333150; PubMed Central PMCID: PMC3968867.
- 37. Pallisgaard N, Clausen N, Schroder H, Hokland P. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript. Genes, chromosomes & cancer. 1999;26(4):355–65. pmid:10534771.
- 38. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacological reviews. 1995;47(2):331–85. Epub 1995/06/01. pmid:7568331.
- 39. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A. 2003;100(13):7977–82. Epub 2003/06/12. pmid:12799470; PubMed Central PMCID: PMCPMC164698.
- 40. Kashyap MK, Kumar D, Villa R, La Clair JJ, Benner C, Sasik R, et al. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B. Haematologica. 2015;100(7):945–54. pmid:25862704; PubMed Central PMCID: PMC4486229.
- 41. Pallis M, Burrows F, Whittall A, Boddy N, Seedhouse C, Russell N. Efficacy of RNA polymerase II inhibitors in targeting dormant leukaemia cells. BMC pharmacology & toxicology. 2013;14(1):32. Epub 2013/06/19. pmid:23767415; PubMed Central PMCID: PMC3685571.
- 42. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. The Journal of biological chemistry. 2009;284(12):8023–32. pmid:19150980; PubMed Central PMCID: PMC2658096.
- 43. Mohammad RM, Goustin AS, Aboukameel A, Chen B, Banerjee S, Wang G, et al. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of Bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both Bcl-2 and Mcl-1. Clinical cancer research: an official journal of the American Association for Cancer Research. 2007;13(7):2226–35. pmid:17404107.
- 44. Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen GM. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell death and differentiation. 2013;20(11):1475–84. pmid:23832116; PubMed Central PMCID: PMC3792441.
- 45. Bodo J, Zhao X, Durkin L, Souers AJ, Phillips DC, Smith MR, et al. Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells. Oncotarget. 2016;7(43):70000–10. Epub 2016/09/24. pmid:27661108; PubMed Central PMCID: PMCPMC5342530.
- 46. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–33. Epub 2011/10/04. pmid:21964340; PubMed Central PMCID: PMC3679520.
- 47. Brunelle JK, Ryan J, Yecies D, Opferman JT, Letai A. MCL-1-dependent leukemia cells are more sensitive to chemotherapy than BCL-2-dependent counterparts. The Journal of cell biology. 2009;187(3):429–42. Epub 2009/12/02. jcb.200904049 [pii] pmid:19948485.
- 48. Perry DK, Carton J, Shah AK, Meredith F, Uhlinger DJ, Hannun YA. Serine palmitoyltransferase regulates de novo ceramide generation during etoposide-induced apoptosis. The Journal of biological chemistry. 2000;275(12):9078–84. pmid:10722759.
- 49. Jaffrezou JP, Levade T, Bettaieb A, Andrieu N, Bezombes C, Maestre N, et al. Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. The EMBO journal. 1996;15(10):2417–24. pmid:8665849; PubMed Central PMCID: PMC450173.
- 50. Ruvolo PP, Deng X, Ito T, Carr BK, May WS. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. The Journal of biological chemistry. 1999;274(29):20296–300. pmid:10400650
- 51. Basu S, Bayoumy S, Zhang Y, Lozano J, Kolesnick R. BAD enables ceramide to signal apoptosis via Ras and Raf-1. The Journal of biological chemistry. 1998;273(46):30419–26. Epub 1998/11/07. pmid:9804808.
- 52. Foight GW, Ryan JA, Gulla SV, Letai A, Keating AE. Designed BH3 peptides with high affinity and specificity for targeting Mcl-1 in cells. ACS chemical biology. 2014;9(9):1962–8. pmid:25052212; PubMed Central PMCID: PMC4168798.
- 53. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer discovery. 2014;4(3):362–75. Epub 2013/12/19. pmid:24346116; PubMed Central PMCID: PMC3975047.
- 54. Adams KW, Cooper GM. Rapid turnover of mcl-1 couples translation to cell survival and apoptosis. The Journal of biological chemistry. 2007;282(9):6192–200. Epub 2007/01/04. pmid:17200126; PubMed Central PMCID: PMC1831535.
- 55. Lee JS, Tang SS, Ortiz V, Vo TT, Fruman DA. MCL-1-independent mechanisms of synergy between dual PI3K/mTOR and BCL-2 inhibition in diffuse large B cell lymphoma. Oncotarget. 2015;6(34):35202–17. pmid:26460954; PubMed Central PMCID: PMC4742099.
- 56. Deng J, Isik E, Fernandes SM, Brown JR, Letai A, Davids MS. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2017. Epub 2017/01/24. pmid:28111464.
- 57. Perez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics. 2017;12(5):323–39. Epub 2016/12/03. pmid:27911230; PubMed Central PMCID: PMCPMC5453193.
- 58. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–9. pmid:11535508
- 59. Nogami A, Oshikawa G, Okada K, Fukutake S, Umezawa Y, Nagao T, et al. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia. Oncotarget. 2015;6(11):9189–205. pmid:25826077; PubMed Central PMCID: PMC4496211.
- 60. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, et al. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Molecular cancer therapeutics. 2014;13(10):2315–27. Epub 2014/07/24. pmid:25053825; PubMed Central PMCID: PMCPMC4185220.
- 61. Lee SC, Dvinge H, Kim E, Cho H, Micol JB, Chung YR, et al. Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med. 2016;22(6):672–8. Epub 2016/05/03. pmid:27135740; PubMed Central PMCID: PMCPMC4899191.
- 62. Busacca S, Law EW, Powley IR, Proia DA, Sequeira M, Le Quesne J, et al. Resistance to HSP90 inhibition involving loss of MCL1 addiction. Oncogene. 2016;35(12):1483–92. pmid:26096930; PubMed Central PMCID: PMC4819782.
- 63. Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK. 2014;28(1):155–65. Epub 2013/04/17. pmid:23588715; PubMed Central PMCID: PMCPMC3883926.
- 64. Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LE, et al. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res. 2008;68(16):6669–79. Epub 2008/08/15. pmid:18701491.